Effects of mutant huntingtin inactivation on Huntington disease‐related behaviours in the BACHD mouse model
Open Access
- 16 December 2020
- journal article
- research article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 47 (4) , 564-578
Abstract
Aims: Huntington disease (HD) is a fatal neurodegenerative disorder with no disease‐modifying treatments approved so far. Ongoing clinical trials are attempting to reduce huntingtin (HTT) expression in the central nervous system (CNS) using different strategies. Yet, the distribution and timing of HTT‐lowering therapies required for a beneficial clinical effect is less clear. Here, we investigated whether HD‐related behaviours could be prevented by inactivating mutant HTT at different disease stages and to varying degrees in an experimental model.Methods: We generated mutant BACHD mice with either a widespread or circuit‐specific inactivation of mutant HTT by using Cre recombinase (Cre) under the nestin promoter or the adenosine A2A receptor promoter respectively. We also simulated a clinical gene therapy scenario with allele‐specific HTT targeting by injections of recombinant adeno‐associated viral (rAAV) vectors expressing Cre into the striatum of adult BACHD mice. All mice were assessed using behavioural tests to investigate motor, metabolic and psychiatric outcome measures at 4–6 months of age.Results: While motor deficits, body weight changes, anxiety and depressive‐like behaviours are present in BACHD mice, early widespread CNS inactivation during development significantly improves rotarod performance, body weight changes and depressive‐like behaviour. However, conditional circuit‐wide mutant HTT deletion from the indirect striatal pathway during development and focal striatal‐specific deletion in adulthood failed to rescue any of the HD‐related behaviours.Conclusions: Our results indicate that widespread targeting and the timing of interventions aimed at reducing mutant HTT are important factors to consider when developing disease‐modifying therapies for HD.Keywords
Funding Information
- Vetenskapsrådet (K2012‐99X‐22330‐01‐5, 2013/03537, 2018/02559)
This publication has 82 references indexed in Scilit:
- Expression of Mutant Huntingtin in Leptin Receptor-Expressing Neurons Does Not Control the Metabolic and Psychiatric Phenotype of the BACHD MousePLOS ONE, 2012
- Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 miceHuman Molecular Genetics, 2012
- Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's DiseaseMolecular Therapy, 2011
- CAG repeats mimic CUG repeats in the misregulation of alternative splicingNucleic Acids Research, 2011
- Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysisNeurobiology of Disease, 2010
- Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopmentBrain, 2010
- Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's diseaseProceedings of the National Academy of Sciences, 2009
- Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's diseaseNeuroscience, 2008
- Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD MiceThe Journal of Neuroscience, 2008
- Adenosine A2A receptors and basal ganglia physiologyProgress in Neurobiology, 2007